Detalhe da pesquisa
1.
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Respir Res
; 24(1): 135, 2023 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210543
2.
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
J Asthma Allergy
; 17: 273-290, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38562251